G A Alexander1, K C Chu, R C Ho. 1. Office of Special Populations Research, National Cancer Institute, Bethesda, MD 20892-7161, USA.
Abstract
PURPOSE: The objectives of this study are to analyze the accrual of Asian Americans to National Cancer Institute (NCI)-supported prevention, screening/diagnosis, and treatment trials and to determine if there is proportional ethnic representation. METHODS: Data were obtained on all participants accrued to ongoing prevention and screening/ diagnosis trials and on all patients accrued to treatment trials from 1994 to mid-1998. In the analysis, the percentage of Asian Americans to the total number of trial participants is calculated. For treatment trials, participants were stratified into five age groups: 0-20 years, 21-44 years, 45-54 years, 55-64 years, and 65 or more years. RESULTS: Asian Americans represented 4.8% of subjects accrued in screening/diagnosis trials, 1.8 to 2.2% of subjects in treatment trials, and 0.9% of subjects in prevention trials. Comparison of treatment trial age groups revealed that younger Asian Americans participate significantly more in treatment trials than older Asian Americans. CONCLUSIONS: Asian American accrual in NCI-supported trials is representative of the cancer burden of Asian Americans in the United States. However, Asian Americans 65+ years are underrepresented. Their full participation in cancer trials is justified.
PURPOSE: The objectives of this study are to analyze the accrual of Asian Americans to National Cancer Institute (NCI)-supported prevention, screening/diagnosis, and treatment trials and to determine if there is proportional ethnic representation. METHODS: Data were obtained on all participants accrued to ongoing prevention and screening/ diagnosis trials and on all patients accrued to treatment trials from 1994 to mid-1998. In the analysis, the percentage of Asian Americans to the total number of trial participants is calculated. For treatment trials, participants were stratified into five age groups: 0-20 years, 21-44 years, 45-54 years, 55-64 years, and 65 or more years. RESULTS: Asian Americans represented 4.8% of subjects accrued in screening/diagnosis trials, 1.8 to 2.2% of subjects in treatment trials, and 0.9% of subjects in prevention trials. Comparison of treatment trial age groups revealed that younger Asian Americans participate significantly more in treatment trials than older Asian Americans. CONCLUSIONS: Asian American accrual in NCI-supported trials is representative of the cancer burden of Asian Americans in the United States. However, Asian Americans 65+ years are underrepresented. Their full participation in cancer trials is justified.
Authors: Latha P Palaniappan; Maria Rosario G Araneta; Themistocles L Assimes; Elizabeth L Barrett-Connor; Mercedes R Carnethon; Michael H Criqui; Gordon L Fung; K M Venkat Narayan; Hamang Patel; Ruth E Taylor-Piliae; Peter W F Wilson; Nathan D Wong Journal: Circulation Date: 2010-08-23 Impact factor: 29.690
Authors: C Daniel Mullins; Lisa Blatt; Confidence M Gbarayor; Hui-Wen Keri Yang; Claudia Baquet Journal: Am J Health Syst Pharm Date: 2005-09-15 Impact factor: 2.637
Authors: Jamie Q Felicitas-Perkins; Melvin Paul Palalay; Charlene Cuaresma; Reginald Cs Ho; Moon S Chen; Julie Dang; William S Loui Journal: Hawaii J Med Public Health Date: 2017-07